Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E6.59 EPS (ttm)10.78 Insider Own0.30% Shs Outstand1.32B Perf Week-3.20%
Market Cap93.92B Forward P/E6.58 EPS next Y10.80 Insider Trans-17.45% Shs Float1.31B Perf Month-4.56%
Income15.08B PEG- EPS next Q2.62 Inst Own76.20% Short Float1.02% Perf Quarter-2.55%
Sales31.58B P/S2.97 EPS this Y62.00% Inst Trans0.16% Short Ratio1.37 Perf Half Y-17.58%
Book/sh12.76 P/B5.57 EPS next Y-5.83% ROA29.30% Target Price95.29 Perf Year-18.25%
Cash/sh9.27 P/C7.66 EPS next 5Y-2.31% ROE93.70% 52W Range70.38 - 101.25 Perf YTD-0.84%
Dividend1.88 P/FCF6.32 EPS past 5Y48.30% ROI45.90% 52W High-29.87% Beta1.12
Dividend %2.65% Quick Ratio1.80 Sales past 5Y32.60% Gross Margin86.50% 52W Low0.90% ATR1.36
Employees8000 Current Ratio1.90 Sales Q/Q-9.60% Oper. Margin60.80% RSI (14)36.22 Volatility1.51% 1.71%
OptionableYes Debt/Eq1.60 EPS Q/Q-18.70% Profit Margin47.70% Rel Volume1.05 Prev Close71.57
ShortableYes LT Debt/Eq1.56 EarningsFeb 07 AMC Payout16.40% Avg Volume9.75M Price71.01
Recom2.20 SMA20-3.64% SMA50-4.07% SMA200-11.20% Volume10,254,937 Change-0.78%
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Oct-03-16Reiterated RBC Capital Mkts Outperform $105 → $95
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Sep-12-16Initiated Berenberg Buy $112
Sep-06-16Upgrade Jefferies Hold → Buy
Jul-29-16Downgrade Argus Buy → Hold
Jul-26-16Reiterated RBC Capital Mkts Outperform $120 → $105
Jul-26-16Downgrade Needham Buy → Hold
Jun-01-16Initiated Gabelli & Co Buy $109
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Feb-12-16Reiterated Maxim Group Buy $137 → $115
Feb-03-16Reiterated RBC Capital Mkts Outperform $130 → $120
Feb-03-16Reiterated Piper Jaffray Overweight $134 → $114
Feb-03-16Reiterated Oppenheimer Outperform $124 → $120
Jan-20-17 04:58PM  Gilead Will Boost HIV, NASH Drugs Amid Hep C Slump; Stock On 2-Week Dip
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Works, Pfizer and Lockheed Martin
09:30AM  Is Gilead Sciences (GILD) a Great Stock for Value Investors?
09:07AM  How Did JNJs Pharmaceuticals Segment Perform in 4Q16?
08:02AM  Are You Undervaluing These 3 Biopharmas' Pipelines? at Motley Fool
05:48AM  European Medicines Agency Validates Gileads Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Business Wire
Jan-19-17 04:41PM  Gilead, Merck, Alexion 2017 Views Hazy; Biogen May Surge: Analyst
01:27PM  Value Investing 2017: 3 Stocks to Put on Your Radar at Motley Fool
12:58PM  Gilead Sciences: The Biggest Driver at Barrons.com
12:56PM  Top Analyst Reports for Gilead Sciences, Las Vegas Sands & Illinois Tool Works
12:29PM  Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors
Jan-18-17 04:33PM  Gilead 2017 Outlook Hamstrung On Hep C, But RBC Bullish On Amgen, Biogen
12:28PM  These 3 Healthcare Stocks Are Ridiculously Cheap at Motley Fool
12:00PM  Buy Stocks You Think Will Survive 'Nuclear Winter'
10:52AM  Gilead Sciences: What to Expect When You're Expecting Earnings at Barrons.com
10:40AM  Orphan Drugs Among 2015's Top 10 Best-Selling Medications
Jan-17-17 09:04AM  3 Bargain Stocks to Buy Now at Motley Fool
Jan-16-17 07:27AM  Is Donald Trump Big Pharma's Worst Nightmare? at Motley Fool
Jan-15-17 11:56AM  Should Investors Bet on Gilead Sciences Version 3.0? at Motley Fool
Jan-14-17 07:59AM  Donald Trump Just Leveled Drug Companies With These 4 Words at Motley Fool
Jan-12-17 12:35PM  Gileads Hepatitis B Drug Vemlidy Approved In EU at Investopedia
11:40AM  Gilead Sciences to Focus on NASH and HIV Drugs at Investopedia
09:43AM  Gilead Sciences: Time for Some M&A Flexibility? at Barrons.com
09:35AM  Biotech Short Sellers Run for Cover
08:40AM  Is the Options Market Predicting a Spike in Gilead Sciences (GILD) Stock?
07:47AM  Gilead (GILD) HBV Drug Vemlidy Receives European Approval
Jan-11-17 05:15PM  Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment
05:01PM  Is Trump the biggest risk to his own rally?
03:46PM  Gilead Sciences: The M&A Question at Barrons.com
01:39PM  Andersen: Take Trump seriously, but not literally
01:26PM  Trump's Comments Are Big Pharma's Nightmare at Forbes
12:26PM  Trump's Comments Are Big Pharma's Nightmare
08:01AM  This Stumbling Biotech Stock Still Has a Lot of Promise at Kiplinger
06:53AM  European Commission Grants Marketing Authorization for Gileads Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection Business Wire
Jan-10-17 05:59PM  Final Trade: GILD, GM & more
05:07PM  Gilead CEO: M&A is top of mind for us this year
01:40PM  Will This Cure What Ails Valeant Pharmaceuticals? at Motley Fool
12:59PM  Todd Hagopian's Top Biotech Takeover Targets For 2017 at Forbes
12:10PM  10 Best Stocks for Retired Investors at Kiplinger
10:54AM  Is This the Solution to Gilead Sciences' Woes? at Motley Fool
10:54AM  4 Things Gilead Sciences' CEO Says to Expect in 2017 at Motley Fool
10:41AM  Top Biotech Resolutions for 2017 at Motley Fool
10:19AM  Gilead Sciences: How Soon is Now? at Barrons.com
09:00AM  Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research Business Wire
08:35AM  Jefferies Has 5 Top Biotech Stocks to Buy for 2017
Jan-09-17 06:05PM  The 10 Worst Stocks in the Nasdaq in 2016 at Motley Fool
05:41PM  So the Nasdaq Is At a Historical High but the Dow Is Going Opposite Direction
04:24PM  2017 J.P. Morgan Healthcare Conference Roundup at Motley Fool
03:55PM  Monday's Sights, Sounds and Biotech Buzz From the J.P. Morgan Healthcare Conference
12:58PM  Why Ariad Pharmaceuticals Stock Soared Today at Motley Fool
09:30AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Pepsi, United Parcel Services, Twitter and Stanley Black & Decker
Jan-08-17 02:13PM  What If You Considered Gilead Sciences a Start-Up? at Motley Fool
02:00PM  3 Takeover Candidates in the Drug Space
Jan-06-17 12:59PM  Top Research Reports for Pepsi, UPS & Gilead Sciences
10:55AM  Biotech Investing: 3 Bold Predictions for 2017 at Motley Fool
10:28AM  Could Amgen's Patent Victory Be Bad For Medicine? at Forbes
06:04AM  Here's Why You Should Sell Gilead, PPG, 3 More Toxic Stocks Before It's Too Late
Jan-05-17 02:55PM  Gilead Sciences Inc.'s Biggest Failure in 2016 at Motley Fool
02:50PM  Gilead Sciences Must Answer to Investors After a Disappointing 2016
11:34AM  Federal Judge Orders State Provide Mumia Abu-Jamal With HCV Treatment by Gilead Sciences, Inc. (GILD) at Insider Monkey
10:00AM  Beaten-Down Gilead Is My Top 2017 Pick
08:24AM  Gilead Sciences, Inc. breached its 50 day moving average in a Bullish Manner : GILD-US : January 5, 2017
07:01AM  Why Gilead Sciences Lost a Staggering 29.2% In 2016 at Motley Fool
06:54AM  Is Biogen Playing With Fire? at Motley Fool
06:21AM  What Biotech Investors Can Expect From the J.P. Morgan Health Care Conference 2017
Jan-04-17 05:19PM  Buy health care despite Obamacare battle?
03:29PM  [$$] Pennsylvania Is Ordered to Provide Hepatitis C Drug to Inmate at The Wall Street Journal
03:04PM  Untreated: Hepatitis C, America's Prison Epidemic at MarketWatch
01:42PM  Gilead Sciences Is Surging -- Here's How to Trade It
11:24AM  Bulls following momentum in Gilead
11:23AM  [$$] The 'final nail in the coffin' for Aids? at Financial Times
10:00AM  Gilead Sciences: With New Hire, M&A Might Be on the Way at Barrons.com
06:04AM  Gilead poaches Novartis cancer specialist Riva
Jan-03-17 04:30PM  Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head Business Wire
10:36AM  Whats the Outlook for Gilead Sciences?
10:28AM  9 Questions for Gilead Sciences at Barrons.com
10:08AM  Forget Gilead Sciences Inc.: These 2 Stocks Doubled Last Year at Motley Fool
09:06AM  The Impact of Gilead Sciences Other Products
07:36AM  Harvoni: Gilead Sciences Blockbuster HCV Drug
Jan-02-17 11:54AM  Biotech Stocks: What to Watch in 2017 at Motley Fool
10:36AM  Gilead Sciences Liver Disease Drugs Portfolio
07:37AM  New Products, Recent Developments for Gilead Sciences
Dec-31-16 12:10AM  [$$] News at Gilead Is Better but Not Good at The Wall Street Journal
Dec-30-16 06:05PM  What Factors Are Contributing to Gilead Sciences Growth?
04:16PM  Gilead Sciences Valuation Compared to Its Peers
03:36PM  January Will Feature Some Of The Market's Most Influential Events
02:31PM  4 Stocks for 2017
02:30PM  2016: Biotechs Tumultuous Year
11:45AM  [$$] News at Gilead Is Better but Not Good at The Wall Street Journal
Dec-29-16 05:00AM  This Army Vet Is Fighting Hep C With Big Pharmas Help at Bloomberg
Dec-28-16 02:33PM  Spring Bank Pharmaceuticals Inc (SBPH) An Ace Up Gilead Sciences, Inc. (GILD)s Sleeve at Insider Monkey
12:28PM  Halftime traders' 2017 playbook: Jon & Pete
10:10AM  Biotech Short Interest Sinks
09:52AM  2 Incredibly Cheap Dividend Stocks at Motley Fool
07:36AM  Whats Behind Amgens Discounted Valuation?
Dec-27-16 11:00AM  Biotech Poised for Rebound
09:41AM  Gilead Sciences: Time to Act Like Incyte? at Barrons.com
Dec-26-16 05:00PM  Gilead Sciences to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9 Business Wire
07:07AM  Will 2017 Be Gilead Sciences Inc.'s Worst Year Yet? at Motley Fool
Dec-24-16 08:15PM  Apple Inc, Gilead and Alphabet Inc: Can Analysts Predict Two Years Into The Future? at Insider Monkey
Gilead Sciences Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company's products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CExecutive ChairmanJan 03Option Exercise21.5873,3371,582,2463,204,433Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanJan 03Sale73.5973,3375,396,9713,131,096Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise16.40100,0001,639,5003,231,096Dec 05 12:54 PM
WILSON GAYLE EDirectorDec 01Option Exercise0.002,1470107,486Dec 05 07:59 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale73.33100,0007,332,8703,131,096Dec 05 12:54 PM
MADIGAN JOHN WDirectorNov 18Option Exercise20.71105,0002,174,025121,761Nov 22 02:45 PM
MADIGAN JOHN WDirectorNov 18Sale74.86105,0007,860,05916,761Nov 22 02:45 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 09Sale79.0010,000790,000122,964Nov 14 01:03 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise16.40100,0001,639,5003,231,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale73.76100,0007,376,0463,131,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanOct 03Option Exercise16.40100,0001,639,5003,231,096Oct 05 12:52 PM
MARTIN JOHN CExecutive ChairmanOct 03Sale77.63100,0007,762,9613,131,096Oct 05 12:52 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 22Sale81.845,000409,220132,964Sep 26 04:54 PM
MILLIGAN JOHN FPresident and CEOSep 06Option Exercise20.7470,0001,451,8001,128,963Sep 08 01:35 PM
MILLIGAN JOHN FPresident and CEOSep 06Sale77.7470,0005,442,0801,058,963Sep 08 01:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise16.40100,0001,639,5003,231,096Sep 06 02:40 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale77.48100,0007,748,3633,131,096Sep 06 02:40 PM
Lofton Kevin EDirectorAug 24Sale81.973,500286,8990Aug 25 05:05 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise39.132,00078,25564,305Aug 03 04:48 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise16.40100,0001,639,5004,119,727Aug 03 04:51 PM
MILLIGAN JOHN FPresident and CEOAug 01Option Exercise20.7470,0001,451,8001,128,963Aug 03 04:53 PM
MILLIGAN JOHN FPresident and CEOAug 01Sale70.9470,0004,965,5901,058,963Aug 03 04:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale80.50100,0008,049,7854,019,727Aug 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Sale79.812,000159,62062,305Aug 03 04:48 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500063,622Aug 02 04:43 PM
MILLIGAN JOHN FPresident and CEOJul 05Option Exercise16.40112,0001,836,2401,170,963Jul 07 02:50 PM
MILLIGAN JOHN FPresident and CEOJul 05Sale84.33112,0009,444,9211,058,963Jul 07 02:50 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise24.912,00049,81063,122Jul 06 01:26 PM
MARTIN JOHN CExecutive ChairmanJul 01Option Exercise16.40100,0001,639,5004,119,727Jul 06 01:28 PM
MARTIN JOHN CExecutive ChairmanJul 01Sale84.73100,0008,472,5234,019,727Jul 06 01:28 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Sale83.122,000166,25061,122Jul 06 01:26 PM
MILLIGAN JOHN FPresident and CEOJun 06Option Exercise16.40112,0001,836,2401,170,963Jun 08 06:59 PM
MILLIGAN JOHN FPresident and CEOJun 06Sale86.94112,0009,736,7791,058,963Jun 08 06:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Option Exercise24.912,00049,81063,122Jun 03 04:46 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise16.40100,0001,639,5004,119,727Jun 03 04:51 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale86.72100,0008,671,9504,019,727Jun 03 04:51 PM
Carter Paul RutherfordEVP Commercial OpsJun 01Sale87.022,000174,04061,122Jun 03 04:46 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Option Exercise33.8857,0921,934,021118,214Jun 02 04:35 PM
Carter Paul RutherfordEVP Commercial OpsMay 31Sale86.8557,0924,958,60061,122Jun 02 04:35 PM
MARTIN JOHN CExecutive ChairmanMay 02Option Exercise16.40100,0001,639,5004,119,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Option Exercise16.40112,0001,836,2401,170,963May 04 02:49 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Option Exercise39.132,00078,25563,122May 04 04:23 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Sale88.722,000177,44861,122May 04 04:23 PM
MILLIGAN JOHN FPresident and CEOMay 02Sale87.71112,0009,823,9541,058,963May 04 02:49 PM
MARTIN JOHN CExecutive ChairmanMay 02Sale87.82100,0008,781,6944,019,727May 04 02:44 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Option Exercise26.9935,874968,239177,964Apr 21 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Sale100.0140,0004,000,574137,964Apr 21 01:28 PM
MILLIGAN JOHN FPresident and CEOApr 04Option Exercise16.40112,0001,836,2401,170,963Apr 05 07:30 PM
MILLIGAN JOHN FPresident and CEOApr 04Sale94.59112,00010,593,9041,058,963Apr 05 07:30 PM
MARTIN JOHN CExecutive ChairmanApr 01Option Exercise16.40100,0001,639,5004,119,727Apr 05 07:49 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise24.912,00049,81063,122Apr 05 06:36 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale91.342,000182,68061,122Apr 05 06:36 PM
MARTIN JOHN CExecutive ChairmanApr 01Sale93.24100,0009,323,5074,019,727Apr 05 07:49 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale91.235,000456,158142,090Apr 05 07:45 PM
Alton Gregg HEVP, Corp & Med AffairsMar 14Sale90.005,000450,000147,090Mar 15 07:31 PM
MARTIN JOHN CChairman and CEOMar 01Option Exercise16.40100,0001,639,5004,119,727Mar 03 02:47 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Option Exercise16.40112,0001,836,2401,170,963Mar 03 02:54 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Option Exercise24.912,00049,81063,122Mar 03 03:10 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Sale87.902,000175,80061,122Mar 03 03:10 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Sale87.79112,0009,832,9951,058,963Mar 03 02:54 PM
MARTIN JOHN CChairman and CEOMar 01Sale88.58100,0008,857,8544,019,727Mar 03 02:47 PM
Washington Robin LEVP, CFOFeb 16Sale90.726,250567,00084,688Feb 18 07:59 PM
MARTIN JOHN CChairman and CEOFeb 01Option Exercise16.40100,0001,639,5004,048,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Option Exercise39.142,00078,27150,783Feb 03 05:42 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Sale82.322,000164,64048,783Feb 03 05:42 PM
MARTIN JOHN CChairman and CEOFeb 01Sale83.42100,0008,342,4753,948,066Feb 03 05:43 PM